Itraconazole: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Antifungal *Dosage Forms: Capsule, solution (for oropharyngeal/esophageal candida) *Routes of Administration: *Common Trade Names: ==Adult Dosing==...") |
Elcatracho (talk | contribs) |
||
| (9 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Antifungal | *Type: [[Antifungal]] | ||
*Dosage Forms: Capsule, solution (for oropharyngeal/esophageal candida) | *Dosage Forms: Capsule, solution (for oropharyngeal/esophageal candida) | ||
*Routes of Administration: | *Routes of Administration: | ||
*Common Trade Names: | *Common Trade Names: Sporanox, Sporaz, Orungal | ||
==Adult Dosing== | ==Adult Dosing== | ||
* | *200mg PO 1-4 times per day | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
* > 5y: 2.5- | *> 5y: 2.5-10mg/kg 2-3 times per day | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
| Line 26: | Line 26: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*CHF, pulmonary edema | *[[CHF]], pulmonary edema | ||
*Hepatotoxicity | *Hepatotoxicity | ||
*SJS/TEN | *SJS/TEN | ||
*Pancreatitis | *[[Pancreatitis]] | ||
===Common=== | ===Common=== | ||
*Nausea/vomiting, diarrhea, abdominal pain | *Nausea/vomiting, diarrhea, abdominal pain | ||
| Line 39: | Line 39: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: 32-96h | *Half-life: 32-96h | ||
*Metabolism: Hepatic, P450 CYP3A4 | *Metabolism: Hepatic, [[P450]] CYP3A4 | ||
*Excretion: | *Excretion: Urine, Feces | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
| Line 47: | Line 47: | ||
==See Also== | ==See Also== | ||
*[[Antifungals]] | |||
*[[Fungal infections]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 03:23, 8 March 2021
Administration
- Type: Antifungal
- Dosage Forms: Capsule, solution (for oropharyngeal/esophageal candida)
- Routes of Administration:
- Common Trade Names: Sporanox, Sporaz, Orungal
Adult Dosing
- 200mg PO 1-4 times per day
Pediatric Dosing
- > 5y: 2.5-10mg/kg 2-3 times per day
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
Renal Dosing
- Adult: No adjustment
- Pediatric:
Hepatic Dosing
- Adult: No adjustment
- Pediatric:
Contraindications
- Allergy to class/drug
- Concomitant use of CYP3A4 substrates (e.g. ergots, lurasidone, methadone, oral midazolam, simvastatin, ticagrelor, and triazolam)
- Ventricular dysfunction (relative)
Adverse Reactions
Serious
- CHF, pulmonary edema
- Hepatotoxicity
- SJS/TEN
- Pancreatitis
Common
- Nausea/vomiting, diarrhea, abdominal pain
- Headache, dizziness
- Edema
- Pruritus, rash
- URI symptoms
Pharmacology
- Half-life: 32-96h
- Metabolism: Hepatic, P450 CYP3A4
- Excretion: Urine, Feces
Mechanism of Action
- Inhibits synthesis of ergosterol (fungal cell membrane component)